Skip survey header

2017 Clinical Conference Evaluation & Post Test-Enduring Materials Format: New Labeling rule; Pregnancy


April 18, 2017- Evaluation - New Labeling Rule; Pregnancy, Lactation, Reproductive Age Women, Presented by; Patricia Geraghty, FNPBC
Estimated Time to complete the activity is 45 minutes. Activity and content expires: 04-18-2020
Statement of disclosure: The planners and faculty for this activity have no relevant financial relationships with commercial interests. No others individuals involved in the planning or presentation of this activity have any relevant financial relationships with commercial interests to disclose.
Accreditation Statement: John Muir Health is accredited by the Institute for Medical Quality/California Medical Association (IMQ/CMA) to provide continuing medical education for physicians.
Credit Designation Statement: John Muir Health designates this enduring material for a maximum of one (.75) AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 
Minimum level of achievement:   Must score 75% correct on posttest and complete the statement of how you will improve your practice after participation is mandatory.
JMH Internet Policy:
1. Physician Info
This question requires a valid date format of MM/DD/YYYY.
3. As a result of attending this CME activity, which of these do you plan to implement and/or change in your practice? *This question is required.
Space Cell DefinitelyMaybeNo Change
Differentiate between older and newer treatment options.
Formulate and communicate treatment plans for the management of medically and socially complex patients
Apply best practice strategies to overcome co-morbidities in medically and socially complex patients
Utilize EBM Guidelines for a multitude of conditions that are encountered in primary care
Apply Tips and Tricks for navigating Epic
Utilize Patient Centered Care skill to help patients become better informed and more involved in their health care decisions
7. The session’s content matched my scope of care
8. The presentation was unbiased.
9. Ample time was provided for discussion and interaction with the speaker(s.)
10. The FDA Labeling now includes risk associated with taking the medication while breastfeeding.
11. The transmission of drugs and other substances across the placenta is primarily via passive diffusion.
12. The FDA labeling 
13. The following disease states are more likely to include teratogens in the treatment options